Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Johan W. Mouton"'
Autor:
Nizar Andria, Anat Stern, Nadya Rakovitsky, Lena E. Friberg, Rosa Zampino, Amos Adler, Yael Zak-Doron, Yehuda Carmeli, Patrizia Murino, Noa Eliakim, Roni Bitterman, Lorenzo Bertolino, Giuseppe Giuffre, Jonathan Lellouche, Mariano Bernardo, Antonio Corcione, Antigoni Kotsaki, Hiba Zayyad, Anastasia Antoniadou, Johan W. Mouton, Tanya Babich, Neta Petersiel, Amir Karban, Domenico Iossa, Giuseppe Ruocco, Vered Daitch, Ami Neuberger, Oren Zusman, George L. Daikos, Sergey Altunin, Roberto Giurazza, Noa Eliakim-Raz, Ursula Theuretzbacher, Yael Dishon, Mical Paul, Emanuele Durante-Mangoni, Yael Dishon Benattar, Dafna Yahav, Leonard Leibovici, Anna Skiada, Inbar Levi, Michal Elbaz, Giusi Cavezza, Heyam Atamna, Elizabeth Temkin, Amichay Hameir, Amir Nutman, Yaakov Dickstein, Marina Raines, Roberto Andini, Fidi Koppel, Maria Galdo, Ioannis Pavleas, Adriano Cristinziano
Publikováno v:
Clinical Microbiology and Infection. 28:73-78
Objectives Mortality among patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections varies between studies. We examined whether in vivo fitness of CRAB strains is associated with clinical outcomes in patients with CRAB infections.
Autor:
Johanna, Berkhout, Maria J, Melchers, Anita C, van Mil, Claudia M, Lagarde, Wright W, Nichols, Johan W, Mouton
Publikováno v:
Journal of chemotherapy (Florence, Italy). 33(6)
The post-antibiotic effect (PAE) of ceftazidime-avibactam
Autor:
Maria-Ioanna, Beredaki, Panagiota-Christina, Georgiou, Maria, Siopi, Lamprini, Kanioura, David, Andes, Maiken Cavling, Arendrup, Johan W, Mouton, Joseph, Meletiadis
Publikováno v:
Antimicrob Agents Chemother
CLSI and EUCAST susceptibility breakpoints for voriconazole and Candida albicans differ by one dilution (≤0.125 and ≤0.06 mg/liter, respectively) whereas the epidemiological cutoff values for EUCAST (ECOFF) and CLSI (ECV) are the same (0.03 mg/li
Autor:
J. Teague, P. Warn, Daniel Obrecht, Glenn E. Dale, J. Hansen, Maria J. Melchers, Johan W. Mouton, Achim Wach, Francesca Bernardini
Publikováno v:
Antimicrobial Agents and Chemotherapy, 63, 3
Antimicrobial Agents & Chemotherapy, 63(3):e01699-18. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 63
Antimicrobial Agents & Chemotherapy, 63(3):e01699-18. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 63
Murepavadin (POL7080) represents the first member of a novel class of outer membrane protein-targeting antibiotics. It specifically interacts with LptD and inhibits lipopolysaccharide (LPS) transport. Murepavadin is being developed for the treatment
Publikováno v:
Antimicrobial Agents & Chemotherapy, 60(12), 7272-7279. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 60, 7272-9
Antimicrobial Agents and Chemotherapy, 60, 12, pp. 7272-9
Antimicrobial Agents and Chemotherapy, 60, 7272-9
Antimicrobial Agents and Chemotherapy, 60, 12, pp. 7272-9
Ceftolozane is a new broad-spectrum cephalosporin and is combined with tazobactam to broaden the activity of ceftolozane against strains producing extended-spectrum beta-lactamases (ESBLs). We determined the pharmacodynamics (PD) of the combination i
Autor:
Eleftheria Mavridou, Ria J. B. Melchers, Eric Mangin, Anita C. van Mil, Mary Motyl, Johan W. Mouton
Publikováno v:
Antimicrobial Agents and Chemotherapy, 59, 790-5
Antimicrobial Agents & Chemotherapy, 59(2), 790-795. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 59, 2, pp. 790-5
Antimicrobial Agents & Chemotherapy, 59(2), 790-795. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 59, 2, pp. 790-5
MK7655 is a newly developed beta-lactamase inhibitor of class A and class C carbapenemases. Pharmacokinetics (PK) of imipenem-cilastatin (IMP/C) and MK7655 were determined for intraperitoneal doses of 4 mg/kg to 128 mg/kg of body weight. MIC and phar
Autor:
Claudia M. Lagarde, A.C. Van Mil, Seyedmojtaba Seyedmousavi, Maria J. Melchers, Eleftheria Mavridou, Johan W. Mouton
Publikováno v:
Antimicrobial Agents and Chemotherapy, 59, 6, pp. 3373-6
Antimicrobial Agents and Chemotherapy, 59, 3373-6
Antimicrobial Agents & Chemotherapy, 59(6), 3373-3376. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 59, 3373-6
Antimicrobial Agents & Chemotherapy, 59(6), 3373-3376. American Society for Microbiology
Ceftolozane is a new cephalosporin with activity against Gram-negative and Gram-positive microorganisms. However, the compound is susceptible to degradation by extended-spectrum beta-lactamases (ESBLs). Tazobactam is an ESBL inhibitor and is combined
Autor:
Anita C. van Mil, Johanna Berkhout, Claudia M. Lagarde, Wright W. Nichols, Seyedmojtaba Seyedmousavi, Johan W. Mouton, Maria J. Melchers
Publikováno v:
Antimicrobial Agents and Chemotherapy, 59, 4, pp. 2299-304
Antimicrobial Agents and Chemotherapy, 59, 2299-304
Antimicrobial Agents & Chemotherapy, 59(4), 2299-2304. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 59, 2299-304
Antimicrobial Agents & Chemotherapy, 59(4), 2299-2304. American Society for Microbiology
Ceftazidime and the β-lactamase inhibitor avibactam constitute a new, potentially highly active combination in the battle against extended-spectrum-β-lactamase (ESBL)-producing bacteria. To determine possible clinical use, it is important to know t
Autor:
Bas C. Mourik, Hannelore I. Bax, Jurriaan E. M. de Steenwinkel, Gerjo J. de Knegt, Johan W. Mouton, Annelies Verbon
Publikováno v:
Antimicrobial Agents & Chemotherapy, 61(10):e00696-17. American Society for Microbiology
Mycobacterium tuberculosis Beijing strains are associated with lower treatment success rates in tuberculosis (TB) patients. In contrast, laboratory strains such as H37Rv are often used in preclinical tuberculosis models. Therefore, we explored the im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::198f8855462795e4ec623ab30581289e
https://pure.eur.nl/en/publications/92f3113a-0139-48be-9199-0c463a466739
https://pure.eur.nl/en/publications/92f3113a-0139-48be-9199-0c463a466739
Publikováno v:
Antimicrobial Agents and Chemotherapy, 61, e00267-17-e00267-17
Antimicrobial Agents and Chemotherapy, 61, 9, pp. e00267-17-e00267-17
Antimicrobial Agents and Chemotherapy, 61(9)
Antimicrobial Agents & Chemotherapy, 61(9):e00267-17. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 61, 9, pp. e00267-17-e00267-17
Antimicrobial Agents and Chemotherapy, 61(9)
Antimicrobial Agents & Chemotherapy, 61(9):e00267-17. American Society for Microbiology
The lack of new antibiotics has prompted investigation of the combination of two existing agents—cefepime, a broad-spectrum cephalosporin, and tazobactam—to broaden their efficacy against extended-spectrum beta-lactamase (ESBL)-producing Enteroba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::771e13a23e3e38ef0663ca00fbaaa3c1
https://doi.org/10.1128/AAC.00267-17
https://doi.org/10.1128/AAC.00267-17